Federal lawsuits against manufacturers of testosterone replacement therapies alleging the companies withheld risks associated with the products will be consolidated in the U.S. District Court for the Northern District of Illinois. The U.S. Judicial Panel on Multidistrict Litigation (MDL) ordered all federal lawsuits involving testosterone supplements be tried in Chicago.
Consolidating the lawsuits is intended to reduce the cost of expert discovery, facilitate the establishment of a uniform pretrial approach to the cases, reduce the potential for inconsistent rulings and conserve resources, the MDL panel wrote.
Testosterone replacement therapies, including the widely prescribed AndroGel, Testim and Axiron are designed to boost testosterone levels and relieve symptoms of so-called “Low T” such as diminished sex drive, fatigue, weight gain and muscle loss. The drugs are currently under investigation by the Food and Drug Administration (FDA) after studies linked the hormone supplements to heart attacks, strokes and death. As a part of that ongoing investigation, the FDA has warned that evidence shows the drugs can increase the risk for dangerous blood clots.
Based on the safety concerns, consumer groups are calling for the FDA to add a black box warning to the products to alert consumers of the serious risks associated with the products.
Testosterone treatment manufacturers, including AndroGel’s Abbvie and Abbott Laboratories, face 45 lawsuits filed in courts across the country, which have now been consolidated into the MDL. Experts say the number of lawsuits within the MDL could climb into the thousands in the months ahead.
Source: Drug Watch